![]() ![]() Ionis Pharmaceuticals Inc’s trailing 12-month revenue is $576.0 million with a -57.1% net profit margin. Blueprint Medicines Corp does not currently pay a dividend.Ĭurrently, Ionis Pharmaceuticals Inc does not have a price-earnings ratio. Analysts expect adjusted earnings to reach $-9.695 per share for the current fiscal year. Year-over-year quarterly sales growth most recently was 1.0%. Blueprint Medicines Corp’s trailing 12-month revenue is $204.6 million with a -284.0% net profit margin. Blueprint Medicines Corp’s stock is NA in 2023, NA in the previous five trading days and up 27.81% in the past year.Ĭurrently, Blueprint Medicines Corp does not have a price-earnings ratio. Latest Biotechnology & Medical Research and Blueprint Medicines Corp, Ionis Pharmaceuticals Inc Stock NewsĪs of June 16, 2023, Blueprint Medicines Corp had a $3.7 billion market capitalization, compared to the Biotechnology & Medical Research median of $103.7 million. Its cardiovascular medicine in development includes Eplontersen, Olezarsen, Pelacarsen, Fesomersen, ION904 and IONIS-AGT-LRx. ![]() ![]() The Company has over seven medicines in Phase III studies for nine indications, which include Eplontersen (TTR), Olezarsen (ApoC-III), Donidalorsen (PKK), ION363 (FUS), Pelacarsen (Apo(a)), Tofersen (SOD1) and Bepirovirsen. WAYLIVRA is an antisense medicine indicated as an adjunct to diet in adult patients. TEGSEDI is for the treatment of patients with polyneuropathy caused by hereditary transthyretin (TTR), amyloidosis (hATTR), a debilitating, progressive, and fatal disease. SPINRAZA is for the treatment of patients with spinal muscular atrophy (SMA), a progressive, debilitating and often fatal genetic disease. The Company?s products include SPINRAZA, TEGSEDI and WAYLIVRA. The Company is primarily focused on cardiovascular and neurology franchises. ![]() is engaged in discovering and developing ribonucleic acid (RNA)-targeted therapeutics. It is developing elenestinib (BLU-263), an investigational, orally available, potent and highly selective KIT inhibitor, for the treatment of indolent SM and other mast cell disorders. Its pipelines also include Elenestinib (BLU-263) (KIT), AYVAKIT (avapritinib) (KIT), Wild-type KIT research program, GAVRETO (pralsetinib) (RET), BLU-945 (EGFR), BLU-525 (EGFR), BLU-451 (EGFR exon 20 insertions), BLU-222 (CDK2), AYVAKIT (PDGFRA), GAVRETO (RET), BLU-222 (CDK2) and BLU-852 (MAP4K1). The Company delivers its approved medicines, including AYVAKIT/AYVAKYT (avapritinib) and GAVRETO (pralsetinib), to patients in the United States and Europe, and it is globally advancing multiple programs for systemic mastocytosis (SM), lung cancer, breast cancer and other genomically defined cancers, and cancer immunotherapy. Read on to learn how Blueprint Medicines Corp and Ionis Pharmaceuticals Inc compare based on key financial metrics to determine which better meets your investment needs.Ībout Blueprint Medicines Corp and Ionis Pharmaceuticals Incīlueprint Medicines Corporation is a global precision therapy company that is inventing medicines for people with cancer and blood disorders. If you’re on the fence about investing in Blueprint Medicines Corp or Ionis Pharmaceuticals Inc because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision. Sifting through countless of stocks in the Biotechnology & Medical Research industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |